The Role of Fat‐Storing Cells in Disse Space Fibrogenesis in Alcoholic Liver Disease

Yukihito Minato, Yasushi Hasumura, Jugoro Takeuchi – 1 January 1983 – Liver biopsy samples from 40 chronic alcoholic patients, including 9 with minimal changes of the liver, 6 with mild hepatic fibrosis, 14 with moderate fibrosis, and 11 with severe fibrosis (cirrhosis) were studied by electron microscopy to assess fibrogenesis in the Disse space and the role of fat‐storing cells in this process. In the Disse space of normal liver, collagen fibers are few, and while lipid droplets containing fat‐storing cells exist, their rough endoplasmic reticulum (RER) is inconspicuous.

Cimetidine Does Not Reduce Liver Blood Flow in Cirrhosis

J. Michael Henderson, Shakir Z. Ibrahim, William J. Millikan, Michael Santi, W. Dean Warren – 1 January 1983 – Cimetidine has been shown to reduce liver blood flow, as measured by indocyanine green clearance, in normal subjects. Concern over the potential deleterious effects of such reduction in cirrhosis led to the measurement of blood flow in 14 cirrhotics receiving oral or intravenous cimetidine. Liver blood flow was measured by the clearance of galactose at steady state during infusion of 40 mg per min.

Chemoprotective Effects of Two Dithiolthiones and of Butylhydroxyanisole Against Carbon Tetrachloride and Acetaminophen Toxicity

Sherry S. Ansher, Patrick Dolan, Ernest Bueding – 1 January 1983 – Administration of tert‐butyl‐4‐hydroxyanisole or of two dithiolthiones to female CD‐I mice protected against the acute toxic effects of two hepatotoxic agents, acetaminophen and carbon tetrachloride. Reduced mortality of mice was observed following pretreatment with tert‐butyl‐4‐hydroxyanisole or dithiolthiones. Pretreatment reduced or prevented hepatic glutathione depletion produced by these two hepatotoxic agents.

Randomized Controlled Trial of Quinacrine for the Treatment of HBsAg‐Positive Chronic Hepatitis

Henry C. Bodenheimer, Fenton Schaffner, Salvatore Vernace, Shalom Z. Hirschman, Judith D. Goldberg, Thomas Chalmers – 1 January 1983 – Several drugs which react with DNA decrease hepatitis B viral (HBV) DNA polymerase activity in vitro. Because such an alteration of viral replication, if produced in patients with hepatitis B surface antigen (HBsAg)‐positive chronic hepatitis, may lead to elimination of viral infection, we conducted a controlled trial of the use of the intercalating agent, quinacrine hydrochloride, in treatment of HBsAg‐positive chronic hepatitis.

Subscribe to